TABLE 3.

Univariate and multivariate analysis for PFS and OS in metastatic breast cancer patients (n = 64).

Univariate analysis
Cox regression	PFS		OS
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (<63 vs ≥ 63)	1.46 (0.867–2.458)	0.155	1.169 (0.680–2.010)	0.572
Menopausal status (pre vs post)	1.049 (0.624–1.734)	0.879	1.063 (0.606–1.865)	0.830
PS (2–3 vs 0–1)	1.723 (0.933–3.182)	0.082	2.031 (1.069–3.860)	0.030*
Disease status (recurrent vs de novo)	2.544 (1.412–4.584)	0.002*	1.389 (0.778–2.481)	0.266
Grade (III vs I/II)	1.352 (0.800–2.283)	0.260	1.597 (0.898–2.840)	0.111
ER status (negative vs positive)	1.023 (0.546–1.916)	0.944	1.178 (0.619–2.243)	0.618
PR status (negative vs positive)	1.389 (0.798–2.418)	0.245	1.120 (0.623–2.011)	0.705
HER2 (positive vs negative)	1.020 (0.575–1.810)	0.946	1.010 (0.548–1.862)	0.975
Visceral metastasis (yes vs no)	1.485 (0.699–3.153)	0.304	1.143 (0.537–2.436)	0.729
Non visceral metastasis (yes vs no)	1.064 (0.536–2.112)	0.859	1.421 (0.669–3.020)	0.361
miR-10b (low vs high)	1.845 (1.087–3.131)	0.023*	1.756 (1.010–3.082)	0.046*
miR-19a (low vs high)	1.431 (0.865–2.369)	0.163	1.180 (0.688–2.024)	0.548
miR-20a (low vs high)	1.367 (0.826–2.262)	0.224	1.475 (0.860–2.529)	0.158
miR-126 (low vs high)	1.211 (0.735–1.995)	0.453	1.254 (0.731–2.151)	0.411
miR-155 (low vs high)	1.437 (0.868–2.379)	0.158	1.320 (0.760–2.263)	0.314
Multivariate analysis
PS (2–3 vs 0–1)			2.031 (1.069–3.860)	0.03*
Disease status (recurrent vs de novo)	2.657 (1.462–4.831)	0.001*
miR-10b (low vs high)	1.920 (1.126–3.273)	0.017*

PFS, progression free survival; OS, overall survival; HR, hazard ratio; CI, confidence intervals; PS, performance status; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; *p < 0.05.